

Special Issue

Advances in Parasite Vaccines

Message from the Guest Editor

Several Parasites lives on or in the human or other animal hosts and cause many serious diseases. In humans, the three main classes of disease-causing parasites are protozoa, helminths, and ectoparasites. Among Protozoan parasites, malaria, caused by the Plasmodium parasite, remains one of the most significant public health problems. The elimination of parasite diseases such as malaria will probably ultimately depend on the development of combining multiple vaccines with the partial efficacy of targeting different stages of infection. To discuss recent advances in the vaccine against various parasitic disease including malaria, , leishmania, Toxoplasmosis, trypanosomiasis, babesiosis, chagas disease, and others parasitic diseases, we invite you to contribute to Special Issue “Advances in Parasite Vaccines”. The issue will also encompass studies underlying immunity to the parasites that cause these diseases. This Special Issue will feature articles related to parasite vaccines, adjuvants, systems immunology, structural vaccinology, computational tools and new approaches, and nanoparticle- and host-directed therapy to boost vaccine efficacy.

Guest Editor

Dr. Gunjan Arora

Section of Infectious Diseases, Yale School of Medicine, Yale university, New Haven 06519, CT, USA

Deadline for manuscript submissions

closed (30 September 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/43089

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).